DBCO-HSA

By attaching therapeutic agents to HSA via DBCO(DBCO-HSA/DBCO-human serum albumin/DBCO-Albumin from human serum/Human serum albumin-DBCO),the pharmacokinetics of the drug can be modified, leading to prolonged circulation times and targeted delivery to tissues expressing particular receptors or characteristics.

DBCO is often used in bioconjugation strategies to covalently link proteins, peptides, or other biomolecules to HSA. This is particularly useful in developing targeted therapeutics or diagnostic agents.

Conjugation of imaging agents (e.g., fluorescent markers, radioactive isotopes) to HSA through DBCO facilitates the tracking and visualization of biological processes in medical imaging techniques.

HSA is sometimes used as a carrier for vaccine antigens. By conjugating antigens to HSA, the immune response can be improved due to the stable and biocompatible nature of the protein.

HSA conjugates can also be used to deliver biologically active compounds, enzymes, or hormones effectively, targeting specific tissues or cells based on the characteristics of HSA and the associated payload.

msds of DBCO-HSA